Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company that was focused on developing enzyme-based therapeutics for patients with rare metabolic diseases. Their lead product candidate, pegzilarginase, was developed for the treatment of Arginase 1 Deficiency. Following disappointing Phase 3 trial results for pegzilarginase in 2023, the company underwent significant restructuring, reduced its workforce, and is exploring strategic alternatives. They also have other preclinical programs targeting metabolic diseases.
The headquarters serves as the central hub for corporate operations, research and development leadership, clinical trial management, and strategic decision-making.
Located in a modern office building in downtown Austin, providing access to a vibrant business environment and talent pool.
Following recent restructuring, the work culture is likely focused on resilience, strategic re-evaluation, and dedication to advancing its remaining scientific programs. Emphasis would be on lean operations and collaborative problem-solving.
The Austin location places Aeglea within a dynamic biotech ecosystem, offering opportunities for collaboration and access to skilled professionals. However, its significance is currently tied to its ability to navigate its strategic review.
Aeglea BioTherapeutics is primarily based in the United States. While their clinical trials may have involved international sites, their core operations and physical offices are U.S.-centric. Global functions would have primarily related to clinical trial coordination and potentially future commercialization efforts, which are now under review.
221 W 6th St, Suite 1450
Austin
Texas
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Aeglea BioTherapeutics' leadership includes:
Aeglea BioTherapeutics has been backed by several prominent investors over the years, including:
Aeglea BioTherapeutics has experienced significant leadership changes over the past 12-18 months, including a new CEO appointment and departures corresponding with the company's restructuring efforts after its lead drug candidate's trial results.
Discover the tools Aeglea BioTherapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Aeglea BioTherapeutics likely uses common corporate email formats. The most probable format combines the first initial and last name, or first name.last name.
[first_initial][last]@aegleabio.com
Format
jgoldberg@aegleabio.com
Example
70%
Success rate
GlobeNewswire • February 13, 2024
Aeglea BioTherapeutics announced it received a delinquency notification letter from Nasdaq due to not timely filing its Quarterly Report on Form 10-Q for the period ended September 30, 2023....more
BioSpace • November 14, 2023
Aeglea provided an update on its ongoing strategic review process and reported Q3 financial results, highlighting continued efforts to evaluate all options to maximize shareholder value after pegzilarginase trial disappointment....more
GlobeNewswire • June 26, 2023
Aeglea announced the appointment of Jeffrey Goldberg as President and CEO, succeeding Dr. Anthony Quinn. The company also provided an update on its strategic review following the Phase 3 trial results of pegzilarginase....more
Fierce Biotech • May 1, 2023
Aeglea BioTherapeutics announced a significant workforce reduction and the departure of its CEO Anthony Quinn, M.D., Ph.D., after its lead candidate, pegzilarginase, failed to meet its primary endpoint in a Phase 3 trial for Arginase 1 Deficiency....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Aeglea BioTherapeutics, are just a search away.